Stevanato Group high-speed visual inspection machines will support biologic and vaccine programs at Catalent manufacturing sites in the US and Italy.

Piombino Dese (PD), Italy – October 27, 2020 –  Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery systems has expanded its longstanding collaboration with Catalent, the US-based leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to include the provision and accelerated delivery of advanced visual inspection systems to help with potential solutions to the pandemic.

Stevanato Group's integrated capabilities serving the pharma industry and its proven expertise in visual inspection will allow the company to support Catalent and its customers' biologics and sterile injectable products.

Within the context of an expanded partnership, Catalent has ordered Plus 400 LKD automatic and PWL semi-automatic visual inspection machines from Stevanato Group. Catalent will install the equipment at its sites in Bloomington, Indiana, and Anagni, Italy, to support various customer programs. The quality assurance solutions feature advanced technologies to reliably inspect biologics and sterile injectables, maximizing the detection rate while keeping false rejects low. A nod to the expediency required in the current environment, Stevanato Group is accelerating delivery of the high precision and high throughput equipment by several months.

“Catalent appreciates Stevanato Group’s commitment to delivering these vital inspection machines to our sites ahead of schedule,” says Dominick Marino, Vice President of Global Procurement at Catalent. “This added capability will increase the speed in which we package and supply important medicines for our customers and patients.”

“We understand what is at stake, and our engineers are committed to delivering high-performance inspection machines ahead of schedule to meet Catalent’s needs and expectations,” said Raffaele Pace, Engineering Vice President of Operations, Stevanato Group.

For more information, please contact:

Christopher Dale, Director of PR and Communications at Turchette, cdale@turchette.com

About Stevanato Group

Established in 1949, Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group can offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership. For more information, please visit www.stevanatogroup.com.